transplant
immunocompromis
patient
antimicrobi
use
respiratori
virus
common
pathogen
associ
commun
acquir
pneumonia
present
opportun
interest
stewardship
effort
prolong
antibiot
therapi
set
viral
pneumonia
popul
associ
increas
length
stay
develop
multidrug
resist
organ
use
rapid
diagnost
particularli
respiratori
viru
panel
rvp
recommend
am
initi
reduc
inappropri
antibiot
therapi
effect
rulinginout
common
respiratori
virus
respiratori
viru
polymeras
chain
reaction
pcr
test
laboratori
advantag
high
sensit
fast
turnaround
time
littl
hour
compon
make
attract
tool
am
comparison
standard
respiratori
cultur
howev
conflict
evid
benefici
impact
clinic
outcom
resourc
util
decreas
antibiot
durat
therapi
hospit
length
stay
purpos
studi
evalu
impact
antimicrobi
util
follow
implement
inhous
rvp
coupl
am
audit
feedback
immunocompromis
patient
irbapprov
singlecent
quasiexperiment
studi
intervent
immunocompromis
patient
test
rvp
abstract
antimicrobi
manag
viral
pneumonia
proven
challeng
hospit
immunocompromis
patient
host
factor
contribut
dilemma
diagnost
uncertainti
lack
organ
identif
clinic
statu
patient
respiratori
viru
panel
rvp
use
compar
immunocompromis
patient
receiv
sendout
n
vs
inhous
n
test
antimicrobi
optim
intervent
consist
antivir
additiondiscontinu
antibiot
discontinuationdeescal
modif
immunosuppress
regimen
implement
inhous
test
audit
feedback
turnaround
time
rvp
reduc
hour
p
time
intervent
reduc
hour
p
yet
frequenc
antimicrobi
optim
intervent
unchang
vs
differ
observ
durat
empir
antibiot
therapi
length
stay
overal
discontinu
rate
patient
test
rvp
low
posit
rvp
n
antibiot
stop
case
bacteri
pneumonia
coinfect
confirm
patient
systemat
effort
taken
reduc
antibiot
use
viral
pneumonia
identifi
major
barrier
immunocompromis
popul
observ
respiratori
viru
season
rv
sendout
rvp
test
util
octob
without
am
audit
follow
year
octob
inhous
rvp
detect
respiratori
pathogen
biofir
filmarray
rp
salt
lake
citi
ut
usa
implement
concurr
weekday
am
call
provid
multidisciplinari
educ
use
inhous
rvp
present
distribut
prior
prospect
audit
feedback
rvp
result
pilot
round
pharmacist
am
servic
rvp
analyz
inhous
pm
daili
transplant
patient
patient
immunocompromis
condit
icu
respiratori
tract
infect
test
rvp
includ
pneumonia
diagnosi
discret
critic
care
transplant
team
per
document
progress
discharg
summari
immunocompromis
defin
solid
organ
transplant
sot
hematopoiet
stem
cell
transplant
hsct
anc
cellscc
count
cellscc
receiv
immunosuppressivecytotox
therapi
alkyl
agent
anthracyclin
mtor
calcineurin
inhibitor
thymoglobulin
tnfalpha
inhibitor
agonist
corticosteroid
equival
least
week
prednison
mg
daili
patient
year
age
pregnant
death
discharg
prior
result
rvp
exclud
time
specimen
collect
final
result
electron
medic
record
defin
turnaround
time
studi
power
effect
size
turnaround
time
alpha
power
yield
sampl
size
patient
outcom
interest
empir
antimicrobi
durat
therapi
hospit
length
stay
time
intervent
intervent
consist
antimicrobi
optim
via
deescalationdiscontinu
antibiot
initiationdiscontinu
antivir
modif
immunosuppress
regimen
begin
collect
specimen
hour
follow
rvp
result
empir
durat
therapi
defin
antibiot
therapi
pneumonia
prior
rvp
result
andor
target
therapi
intervent
chisquar
use
categor
variabl
mannwhitneyu
use
continu
nonparametr
variabl
factor
associ
antimicrobi
optim
examin
bivari
analysi
spss
version
use
statist
analys
one
hundr
thirtyon
immunocompromis
patient
test
rvp
analyz
n
n
median
age
year
total
popul
femal
differ
baselin
characterist
sendout
test
inhous
test
except
posit
rvp
chronic
obstruct
pulmonari
diseaseasthma
congest
heart
failur
tabl
among
patient
immunocompromis
factor
renal
liver
lung
common
type
sot
metastat
cancer
immunosuppress
medic
relat
sot
hsct
cellscc
pneumonia
di
hour
p
inhous
rvp
significantli
impact
frequenc
antimicrobi
optim
intervent
vs
reduc
timetointervent
specimen
collect
hour
p
also
differ
group
type
intervent
deescal
tabl
rapid
diagnost
test
quickli
becom
influenti
aspect
stewardship
model
recommend
practic
guidelin
initi
am
program
analyz
immunocompromis
patient
test
inhous
rvp
am
implement
led
signific
reduct
turnaround
time
timetointervent
increas
diagnost
yield
compar
patient
sendout
rvp
test
yet
wide
avail
practic
patient
institut
rvp
gain
popular
practic
judici
use
patient
popul
interpret
respect
result
taken
higher
consider
optim
antimicrobi
manag
cost
care
improv
diagnost
yield
turnaround
time
may
surrog
ancillari
test
laboratori
labor
may
still
justifi
rvp
use
rvp
consist
use
deescal
tool
rather
addit
academ
inform
investig
am
resourc
util
warrant
critic
ill
immunocompromis
transplant
patient
thank
arin
jantz
pharmd
zachari
smith
pharmd
contribut
studi
rci
sl
davi
http
